Liquid Chromatography Mass Spectrometry system

描述（由申请人提供）：自1990年以来，申请在分析实验室共享资源（ALSR）中共享使用来自ThermoElectron Corporation的三级四极杆液相色谱/质谱（LC/MS/MS）TSQ型号Ultra AM，ALSR是夏威夷癌症研究中心/夏威夷大学的核心设施。使用完全由从事生物医学研究的项目，其中绝大多数项目（85%）由NIH资助。随着所要求的LC/MS/MS系统的收购，ALSR将处于独特的位置，在夏威夷运行第一个LC/MS/MS系统。目前资助的13个项目和6个悬而未决的NIH项目所要求的设备的使用，这些项目跨越了非常不同的领域，包括天然产物化学，生物化学，动物研究，流行病学和临床科学，但有大量重叠的研究主题，将极大地促进多学科的协作环境。 LC/MS的工作量将很快超过ALSR的当前容量，这不能通过额外的技术人员时间或可用仪器的方法调整来改善。所要求的LC/MS/MS系统的收购将解决这一问题，并通过提高灵敏度，缩短周转时间，大大扩展可测量分析物的数量，并通过获得最先进的生物分子定量仪器，大大提高了ALSR的能力，这是ALSR服务的主要重点。考虑到采购成本、硬件和软件的可用知识，特别是特殊仪器功能（最高分辨率、高选择性反应监测模式、精确质量选项、独特的Ion Max源、最稳健的离子源、最宽的动态范围、APCI/APPI组合电离模式），所要求的仪器最适合ALSR的需求。工厂工作人员的工作时间将根据需要进行调整。 由于单个用户的成本过于昂贵，并且由于需要有经验的操作员专用于仪器，因此在ALSR中建立的中央共享资源中操作和管理所请求的设备是理想的。自1999年以来，ALSR运行了一个基于离子阱的液相色谱质谱系统（LCQ Surveyor- Advantage），该系统来自同一制造商（ThermoElectron Corporation，前身为Thermo Finnigan），并使用与所需LC/MS/MS仪器相同的软件（Xcalibur）。卡斯特女士自1999年被收购以来一直担任LC/MS设备的操作员，在LC/MS设备的操作、维护、故障排除和维修方面拥有丰富的经验。这一最有价值的专业知识，结合卡斯特女士在ThermoElectron演示实验室对所需仪器的初步测试，将确保所需LC/MS/MS系统顺利过渡到常规操作。即使在所要求的新仪器存在的情况下，目前的LCQ系统将继续以其全部能力用于蛋白质组学，识别已知和未知（天然）产品，以及用于具有相对高浓度或有限数量的所要求分析物的样品。所有这些任务都可以可靠地执行，部分甚至是基于离子阱的LC/MS系统的主要优势。因此，购买LC/MS/MS仪器不仅可以为许多相互关联的NIH项目提供必要的支持并提高其用户的竞争力，而且可以理想地补充ALSR的能力，支持其出色的质量，并最终改善夏威夷的整个研究基础设施。

DESCRIPTION (provided by applicant): A triple-stage quadrupole liquid chromatography mass spectrometry system (LC/MS/MS) TSQ model Ultra AM from ThermoElectron Corporation is requested for shared use in the Analytical Laboratory Shared Resource (ALSR), a core facility of the Cancer Research Center of Hawaii/University of Hawaii since 1990. Usage is exclusively by projects engaged in biomedical research with the overwhelming majority of these projects (85%) being funded by NIH. With the acquisition of the requested LC/MS/MS system the ALSR will be in the unique position to operate the first LC/MS/MS system in Hawaii. The usage of the requested equipment by 13 currently funded and 6 pending NIH projects that span very diverse fields including natural products chemistry, biochemistry, animal research, epidemiology, and clinical sciences, but with substantial overlapping study themes, will greatly foster a collaborative multidisciplinary environment. The LC/MS workload will soon exceed the ALSR's current capacities which cannot be improved by additional technician time or method adjustment of available instrumentation. The acquisition of the requested LC/MS/MS system will solve this problem and greatly advance the capabilities of the ALSR by increasing sensitivity, shortening turn-around-times, expanding vastly the number of measurable analytes, and by obtaining the state-of-the art instrument for quantitation of biomolecules, the major focus of the services in the ALSR. The instrumentation requested is best suited for the needs in the ALSR considering acquisition cost, available knowledge with hardware and software, and particularly, special instrument features (greatest resolution, High Selectivity Reaction Monitoring mode, Accurate Mass option, unique Ion Max source, most robust ion source, widest dynamic range, APCI/APPI combinatorial ionization mode). Facility personnel hours will be adjusted as needed. Due to the prohibitively expensive costs for a single user and due to the needs of an experienced operator dedicated to the instrument the operation and administration of the requested device in a central shared resource as established in the ALSR is ideal. Since 1999, the ALSR has operated one ion trap based liquid chromatography mass spectrometry system (LCQ Surveyor- Advantage), which is from the same manufacturer (ThermoElectron Corporation, formerly Thermo Finnigan) and uses the identical software (Xcalibur) as the requested LC/MS/MS instrument. Ms. Custer, the operator of the LCQ since its acquisition in 1999, has extensive experience in the operation, maintenance, troubleshooting, and repair of LC/MS equipment. This most valuable expertise, in combination with initial tests of the requested instrument by Ms. Custer in ThermoElectron's demonstration laboratory, will ensure a smooth transition into routine operations of the requested LC/MS/MS system. Even in the presence of the requested new instrument, the current LCQ system will continue to be used at its full capacity for proteomics, identification of known and unknown (natural) products, and for samples with relative high concentrations or a limited number of requested analytes. All of these tasks can reliably be performed and are, in part, even major strengths of an ion trap based LC/MS system. The acquisition of the LC/MS/MS instrument would, therefore, not only provide essential support to many interrelated NIH projects and improve the competitiveness of its users, but it would ideally complement the capabilities of the ALSR, support its outstanding quality, and ultimately improve the entire research infrastructure in Hawaii.